Why Medical Technology Investing Needs a Different Playbook

Medical technology investing means buying the companies and funds behind medical devices, surgical robots, diagnostics, and imaging. Most investors gain exposure through a sector ETF such as IHI or XHE, a basket of large-cap leaders like Medtronic and Stryker, or private medtech venture and growth funds. The sector trades on demographics, not the cycle.

Key takeaways

• Medtech is a distinct sector from biotech. Device ETFs like IHI and XHE hold surgical, cardiac, and diagnostic hardware makers, while biotech funds like IBB hold drug developers. The overlap is minimal, so pairing them is diversification, not duplication.
• The global medtech market was about $724 billion in 2024 and is projected to reach roughly $1.01 trillion by 2030, a 5.97% CAGR, per Research and Markets (2025).
• Growth is driven by an aging population, AI diagnostics, surgical robotics, and wearables. Returns are throttled by FDA approval risk, reimbursement decisions, and rich valuations on the highest-growth names.
• A high net worth investor can access the sector three ways: a low-cost ETF for the core, single-stock positions in cash-generative leaders, or private medtech venture and growth equity for asymmetric upside.

What counts as medical technology

Medical technology, or medtech, covers the hardware and software used to diagnose, monitor, and treat patients. It spans surgical robotics, orthopedic and cardiovascular implants, diagnostics and lab equipment, imaging systems, continuous glucose monitors, and connected wearables.

It is not pharmaceuticals or biotech. Drug companies live and die by molecules moving through clinical trials and patent cliffs. Device companies sell physical products that generate recurring revenue through consumables, disposables, and service contracts once a system is installed in a hospital. That razor-and-blade dynamic is why the best medtech names compound steadily rather than lurching on single trial readouts.

The distinction matters for portfolio construction. When you buy a medtech device ETF, you are not buying the same risk as a biotech fund. Confusing the two is the most common mistake retail investors make in this sector.

The major medtech players

The sector is anchored by a handful of large-cap leaders with diversified revenue and durable moats. Figures below are approximate annual device revenue from 2025 to 2026 reporting.

Two names outside the pure-device group deserve mention. Danaher (DHR) and Thermo Fisher Scientific (TMO) are life-sciences and diagnostics platforms rather than device makers, so they sit adjacent to medtech and often appear in broader healthcare funds instead of device-specific ones. Knowing which bucket a company falls into keeps you from doubling up on the same exposure.

The medtech ETFs, and the biotech overlap nuance

For most investors the cleanest entry point is a sector ETF. The two core device funds take opposite approaches to weighting, and a common third fund, IBB, is not a medtech fund at all.

Expense ratios and holdings are as of mid-2026 from iShares and State Street fund data. Verify current figures before you buy.

IHI is the default core holding. It tracks the Dow Jones U.S. Select Medical Equipment Index and is heavily concentrated at the top, with Abbott near 19%, Intuitive Surgical near 13%, and Stryker near 11%. That concentration means IHI behaves like a bet on the established leaders, with lower volatility but muted exposure to emerging innovators.

XHE flips that. Its modified equal-weight design gives smaller and mid-cap companies far more influence, which raises both the upside from emerging winners and the drawdown risk when small caps sell off. It is the more aggressive of the two device funds despite a nearly identical fee.

The IBB nuance is important. IBB is an iShares fund and sits next to IHI alphabetically in many screeners, so investors assume it is more of the same. It is not. IBB holds biotechnology drug developers whose value hinges on clinical trials and FDA drug approvals, a fundamentally different risk profile. Overlap between IBB and IHI is minimal, so holding both adds genuine diversification within healthcare rather than stacking the same bet. If you want device exposure specifically, IBB does not give it to you.

Compared with a broad index like the S&P 500, a medtech ETF is a concentrated sector tilt, not a core holding. It belongs alongside diversified equity exposure such as a total-market or global equity fund, not in place of it.

What is driving medtech growth

• Aging demographics. The over-65 population is the heaviest user of medical devices, from cardiac stents to joint replacements. As that cohort expands across developed markets, procedure volumes and device demand rise on a structural, non-cyclical basis.
• AI diagnostics. Machine-learning tools for radiology, pathology, and early detection are moving from pilots to FDA-cleared products with real revenue. AI shortens diagnosis time and expands the addressable market for screening.
• Surgical robotics. Minimally invasive robotic surgery keeps taking share from open procedures. Intuitive Surgical dominates soft-tissue robotics, and challengers from Medtronic, J&J, and Stryker are pushing into orthopedics and other specialties.
• Wearables and remote monitoring. Continuous glucose monitors, cardiac patches, and connected sensors are shifting care out of the hospital. Improved reimbursement for remote patient monitoring has strengthened the commercial case for these devices.

These drivers are secular, which is the whole appeal. Device demand tracks demographics and clinical adoption rather than the economic cycle, giving the sector a defensive tilt within a growth portfolio.

The main risks

• Regulatory and FDA risk. New devices must clear the FDA. The lighter 510(k) pathway applies to devices similar to something already on the market, while high-risk Class III devices need full Premarket Approval, which takes years and costs far more. A clinical hold or rejection can cut a small-cap device stock by half in a single session. Large diversified names absorb these events; single-product companies do not.
• Reimbursement risk. FDA clearance is necessary but not sufficient. If Medicare and private insurers do not assign a favorable reimbursement code, a cleared device may never reach commercial scale. Reimbursement disappointments have sunk otherwise strong companies, and this risk is highest for genuinely novel technologies without an established payment pathway.
• Valuation risk. The highest-growth medtech names, especially in robotics and AI diagnostics, trade at rich multiples. Intuitive Surgical and similar leaders are priced for continued rapid growth, so any deceleration hits the stock hard. Entry price matters as much here as in any growth sector.
• Technological obsolescence. Innovation moves fast. A device that led in 2020 can face serious competition within a few years, so companies that underinvest in research fall behind quickly.

How a high net worth investor gets exposure

There are three practical routes, and most large portfolios blend them.

Sector ETF for the core. A position in IHI or XHE delivers diversified, low-cost device exposure with daily liquidity. This is the sensible base layer. IHI for a large-cap, lower-volatility tilt, XHE if you want more small and mid-cap innovation. Neither should be confused with a total-market holding; treat it as a satellite sector position, typically a single-digit percentage of equities.

Single-stock leaders. For investors who want to concentrate, the large-cap names offer cash-generative businesses with wide moats and modest but reliable growth. A basket of Medtronic, Abbott, Stryker, Boston Scientific, and Intuitive Surgical captures most of the sector's economics with more control over weighting than an ETF allows. The tradeoff is single-name risk and the diligence burden of tracking pipelines and reimbursement decisions.

Private medtech venture and growth equity. The asymmetric upside lives in private markets, where accredited and high net worth investors can back device companies before they list. Dedicated medtech funds within the broader private equity landscape offer institutional diligence, portfolio construction, and access to deals retail cannot reach. The price is illiquidity, typically a seven-to-ten-year lockup, and binary outcomes on individual companies. This route suits investors with the risk tolerance, holding horizon, and, ideally, domain knowledge to evaluate clinical and regulatory risk.

A common structure for a large portfolio is a barbell: a liquid ETF core for steady sector exposure, plus a smaller allocation to private medtech funds or select single stocks for growth. Size the illiquid portion to money you will not need for a decade, and weight the public core toward the defensive, cash-generative leaders.

For more sector playbooks and vehicle comparisons, see the investing hub.

The bottom line

Medtech is a secular growth sector riding aging demographics, AI diagnostics, robotics, and wearables, with device economics that reward patient holders. The cleanest exposure is a low-cost ETF like IHI or XHE, kept distinct from biotech funds like IBB, which hold a different risk entirely. Layer in single-stock leaders or private medtech funds if you want to concentrate the bet, and respect the sector's real risks: FDA approval, reimbursement, and valuation.

Frequently asked questions

What is the difference between medtech and biotech investing?

Medtech and biotech are distinct sectors with a different risk profile. Device companies sell physical products like implants and surgical robots that generate recurring revenue through consumables and service contracts, so they compound steadily. Biotech drug companies live and die by molecules moving through clinical trials and patent cliffs. Overlap between a device ETF like IHI and a biotech fund like IBB is minimal, so pairing them is diversification, not duplication.

What is the best ETF for medical technology?

IHI, the iShares US Medical Devices ETF, is the default core holding, tracking about 51 US device makers with a 0.37% expense ratio, though it is top-heavy in Abbott, Intuitive Surgical, and Stryker. XHE, the SPDR S&P Health Care Equipment ETF, uses modified equal weight at 0.35%, giving smaller and mid-cap companies more influence and more volatility. IHI suits a large-cap tilt, XHE a more aggressive one.

Is IBB a medical device fund?

No, IBB is not a medtech fund. IBB is the iShares Biotechnology ETF, holding about 250 biotech drug developers whose value hinges on clinical trials and FDA drug approvals, a fundamentally different risk from medical devices. It sits next to IHI alphabetically in screeners, so investors assume it is more of the same, but if you want device exposure specifically, IBB does not give it to you.

What is driving growth in the medical technology sector?

Medtech growth is driven by aging demographics, AI diagnostics, surgical robotics, and wearables. The over-65 population is the heaviest user of medical devices, so procedure volumes rise on a structural, non-cyclical basis. The global medtech market was about $724 billion in 2024 and is projected to reach roughly $1.01 trillion by 2030, a 5.97% CAGR. These drivers track demographics rather than the economic cycle.

What are the main risks of investing in medtech?

The main medtech risks are FDA approval, reimbursement, and valuation. A clinical hold or rejection can cut a small-cap device stock by half in a single session. Even after FDA clearance, if Medicare and private insurers do not assign a favorable reimbursement code, a cleared device may never reach commercial scale. The highest-growth robotics and AI names also trade at rich multiples, so any deceleration hits the stock hard.